🔎 Trials Near Me

Home › Esophageal Adenocarcinoma › North Carolina

Pag-aaral pangklinika para sa Esophageal Adenocarcinoma sa North Carolina

12 pag-aaral para sa Esophageal Adenocarcinoma ang naghahanap ng mga kalahok sa mga site sa North Carolina.

Mga Lungsod sa North Carolina

Opisyal na teksto ng pag-aaral (English)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • at 6 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • at 5 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05677490

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  • University of North Carolina Medical Center, Chapel Hill
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07221149

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

  • Duke University Medical Center, Durham
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07603375

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

  • University of North Carolina at Chapel Hill, Chapel Hill
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 50 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06687603

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06732388

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • University of North Carolina School of Medicine, Chapel Hill
Nagre-recruit
Edad 18 hanggang 89 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05753748

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Charlotte
  • Research Site, Wilmington
  • Research Site, Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07431281

Obeticholic Acid for Prevention in Barrett's Esophagus

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT04939051

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

  • University of North Carolina at Chapel Hill, Chapel Hill
Nagre-recruit
Edad 18 hanggang 89 · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT05530343

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 12, 2026 · NCT07284186

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

  • Durham VA Medical Center, Durham, NC, Durham
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2025 · NCT05563766

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.